HCC Risk Biomarkers

The Situation:

Liver cancer is a leading cause of cancer deaths worldwide.1 Early detection facilitates a greater chance of survival.2 If detected early, the 5 year survival rate increases from 15% up to 70% with appropriate interventional treatment.3

The Challenge:

Surveillance programs facilitate earlier cancer detection, earlier access to curative treatments and greater patient survival.2 46% of enrolled patients in surveillance programs had significant increases in 5 year survival due to early tumor detection.4

How We Help:

Enhance Liver Cancer Surveillance using FUJIFILM’s AFP-L3 and DCP tests

Dr. Yang: Section 1

Dr. Yang: Section 2

Dr. Yang: Section 3

Dr. Yang: Section 4

Dr. Yang: Section 5

Dr. Yang: Section 6

Dr. Yang: Section 7

Dr. Yang: Section 8

Dr. Yang: Section 9

Dr. Yang: Section 10

Dr. Charlton: Case Base HCC Screening & Surveillance

Dr. Charlton: Case Base HCC Screening & Surveillance (5 mins)

Contact Us

Please contact us for further inquiries of FUJIFILM's liver biomarkers AFP-L3 and DCP and uTASWako i30 system.